Figure 2.

Proportion of patients with (a) ISI score of ≤ 7 and (b) a decrease of ≥ 4 points in DLQI score from baseline to the end of the follow‐up period (modified intention‐to‐treat population). Fu2 denotes 8 weeks after the end of the treatment period. Study‐JP01 was double‐blind until week 16 (denoted by shaded area).
BL, baseline; DLQI, Dermatology Life Quality Index; Fu, follow‐up; ISI, Insomnia Severity Iindex.